FDA hurdle cleared for liver cancer drug application: HLB

HLB said Wednesday it received a Voluntary Action Indicated notice from the US Food and Drug Administration after the American authorities had conducted an on-site inspection of the Chinese production site for liver cancer therapy candidate Rivoceranib, reigniting the hopes of getting the FDA’s greenlight for the anti-cancer treatment.

HLB's US subsidiary Elevar Therapeutics received a close-out letter from the FDA regarding the current Good Manufacturing Practice, or cGMP, inspection at its par ...